theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Nuclear Medicine

Neuroendocrine Tumors   

Questions discussed in this category


Can PRRT be used in a patient with a GI neuroendocrine tumor and estimated GFR of less than 30?
1 Answer available
7085


Papers discussed in this category


Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2005-01
Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

J. Nucl. Med.,
NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of Lu-DOTATATE Peptide Receptor Radionuclide Therapy.

Neuroendocrinology, 2017 Apr 13
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasia: Peptide Receptor Radionuclide Therapy with Radiolabeled Somatostatin Analogues.

Related Topics in Nuclear Medicine

  • Radiation Oncology
  • Genitourinary Cancers
  • Medical Oncology
  • Prostate Cancer
  • Hematology
  • Gastrointestinal Cancers
  • Rheumatoid Arthritis
  • Urologic Oncology
  • Urology
  • Imaging

Copyright © 2025 theMednet
All Rights Reserved.